1357171-62-0
中文名称
KC7F2
英文名称
ML-228
CAS
1357171-62-0
分子式
C27H21N5
分子量
415.49
MOL 文件
1357171-62-0.mol
更新日期
2023/10/11 15:49:01
1357171-62-0 结构式
基本信息
中文别名
化合物ML228 英文别名
L-228ML-228
CID-46742353
ML228
ML 228
ML-228
CID-46742353
N-([1,1'Biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine
N-([1,1-Biphenyl]-4-ylmethyl)-6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-5-amine
1,2,4-Triazin-5-amine, N-([1,1'-biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)-
所属类别
生物化工：激动剂抑制剂物理化学性质
沸点686.0±65.0 °C(Predicted)
密度1.228±0.06 g/cm3(Predicted)
储存条件-20°C, Inert atmosphere
溶解度可溶于DMSO（少许）、甲醇（少许）
酸度系数(pKa)2.03±0.63(Predicted)
形态固体
颜色淡黄色至淡黄色
常见问题列表
生物活性
ML228 (CID-46742353) 是一种有效的 HIF 信号通路激活剂，EC50 为 1 μM。ML228 可激活 HIF 以及下游 EGFR。靶点
EC50: 1 μM (HIF)
体外研究
ML228 (CID-46742353) represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications.
体内研究
ML228 (injection; 1 µg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduce SCI secondary injury and promote the recovery of neurological function.
| Animal Model: | SD rat |
| Dosage: | 1 µg/kg |
| Administration: | injection; 7 days |
| Result: | Alleviated SCI of the central nervous system and relieve associated symptoms. |